Lucence Showcases Liquid Biopsy Tech for Earlier Cancer Detection at 2024 ASCO Annual Meeting

News | July 4, 2024

CHICAGO, IL July 4, 2024 — Lucence presented promising new data on earlier cancer detection based on AmpliMark, its amplicon-based next generation sequencing technology at the 60th Annual ASCO Meeting in Chicago, May 31 – Jun 4, 2024.

“Most cancers go undetected until they are at late-stage [1],” said Min-Han Tan, PhD, MBBS, CEO & Medical Director of Lucence. “We look forward to sharing collaborative study results on how earlier cancer detection can be enabled through our liquid biopsy testing.”

Lucence published the following abstract at the ASCO meeting:

#e15042 Poh et al. Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay.

Lucence shared data on a ctDNA mutation-based multi-cancer screening (MCS) liquid biopsy test using its proprietary amplicon-based next-generation sequencing (NGS) testing for detection of cancer-associated alterations. In a cohort of 601 individuals, sensitivity for detection of cancer-associated alterations was 80.9% and specificity was 99.0%.  Overall tissue of origin (TOO) prediction performance was modeled in a simulated cohort based on cancer incidence in Singapore and Hong Kong, yielding accuracies of 87.3% and 88.7% respectively. The data demonstrates that the mutation-based NGS assay is highly sensitive in detecting cancer signals and accurately predicts tumor origin.


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.